Literature DB >> 30805886

Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Ben T Copeland1,2, Hassan Shallal1, Chentian Shen1, Kenneth J Pienta3, Catherine A Foss4, Martin G Pomper5,6.   

Abstract

PURPOSE: Prostate carcinoma consists of tumor epithelium and malignant stroma. Until recently, diagnostic and therapeutic efforts have focused exclusively on targeting characteristics of the tumor epithelium, ignoring opportunities to target inflammatory infiltrate and extracellular matrix components. Prostate tumors are rich in tumor-associated macrophages (TAMs), which can be either of the cytotoxic M1 or protumorigenic M2 phenotype. We have quantified the proportion of each in seven common human prostate tumor lines grown subcutaneously in athymic nude mice and have imaged macrophage densities in vivo in xenografts derived from these lines. PROCEDURES: A panel of seven human prostate cancer xenografts was generated in intact male athymic nude mice reflecting variable expression of the androgen receptor (AR) and prostate-specific membrane antigen (PSMA). Mice were imaged ex vivo using near-infrared fluorescence (NIRF) imaging for PSMA expression and total macrophage densities to enable direct comparison between the two. Tumors were harvested for sectioning and additional staining to delineate M1 and M2 phenotype along with vascular density.
RESULTS: Macrophage polarization analysis of sections revealed that all xenografts were > 94% M2 phenotype, and the few M1-polarized macrophages present were confined to the periphery. Xenografts displaying the fastest growth were associated with the highest densities of macrophages while the slowest growing tumors were characterized by focal, tumor-infiltrating macrophage densities. Xenograft sections displayed a strong positive spatial relationship between macrophages, vasculature, and PSMA expression.
CONCLUSIONS: Prostate TAM disposition can be imaged ex vivo and is associated with growth characteristics of a variety of tumor subtypes regardless of PSMA or AR expression.

Entities:  

Keywords:  DPA-713; Fluorescence imaging; NIRF; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 30805886     DOI: 10.1007/s11307-019-01318-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  56 in total

Review 1.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 2.  Update on 18F-Fluciclovine PET for Prostate Cancer Imaging.

Authors:  Ephraim E Parent; David M Schuster
Journal:  J Nucl Med       Date:  2018-03-09       Impact factor: 10.057

Review 3.  Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

4.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.

Authors:  Kiavash Movahedi; Steve Schoonooghe; Damya Laoui; Isabelle Houbracken; Wim Waelput; Karine Breckpot; Luc Bouwens; Tony Lahoutte; Patrick De Baetselier; Geert Raes; Nick Devoogdt; Jo A Van Ginderachter
Journal:  Cancer Res       Date:  2012-06-19       Impact factor: 12.701

5.  Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Authors:  Osamu Kawai; Genichiro Ishii; Kaoru Kubota; Yukinori Murata; Yoichi Naito; Tetsuya Mizuno; Keiju Aokage; Nagahiro Saijo; Yutaka Nishiwaki; Akihiko Gemma; Syoji Kudoh; Atsushi Ochiai
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

6.  Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; Martin G Pomper; Mohammad E Allaf; Mehrbod Som Javadi
Journal:  Clin Nucl Med       Date:  2016-01       Impact factor: 7.794

Review 7.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

8.  Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.

Authors:  Christina L Grant; Leslie A Caromile; Vivienne Ho; Khayyam Durrani; M Mamunur Rahman; Kevin P Claffey; Guo-Hua Fong; Linda H Shapiro
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

9.  Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.

Authors:  Heng-Chuan Su; Yao Zhu; Guo-Wen Ling; Si-Long Hu; Xiao-Ping Xu; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2017 May-Jun       Impact factor: 3.285

10.  The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy.

Authors:  M Lanciotti; L Masieri; M R Raspollini; A Minervini; A Mari; G Comito; E Giannoni; M Carini; P Chiarugi; S Serni
Journal:  Biomed Res Int       Date:  2014-03-11       Impact factor: 3.411

View more
  4 in total

1.  Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1/STAT pathway in prostate cancer.

Authors:  Jiping Rong; Lu Xu; Yinying Hu; Fan Liu; Yanrong Yu; Hongyan Guo; Xudong Ni; Yanqin Huang; Lin Zhao; Zhigang Wang
Journal:  Cancer Cell Int       Date:  2020-09-29       Impact factor: 5.722

Review 2.  The Roles of Tumor-Associated Macrophages in Prostate Cancer.

Authors:  Chenglin Han; Yuxuan Deng; Wenchao Xu; Zhuo Liu; Tao Wang; Shaogang Wang; Jihong Liu; Xiaming Liu
Journal:  J Oncol       Date:  2022-09-07       Impact factor: 4.501

Review 3.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

4.  Lack of the MHC class II chaperone H2-O causes susceptibility to autoimmune diseases.

Authors:  Robin A Welsh; Nianbin Song; Catherine A Foss; Tatiana Boronina; Robert N Cole; Scheherazade Sadegh-Nasseri
Journal:  PLoS Biol       Date:  2020-02-18       Impact factor: 8.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.